Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Nov 2023 | From Akero Therapeutics

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist (GLP-1RA) in Patients with NASH/MASH and T2D: a Randomized, Placebo-controlled Study (Cohort D)

Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Tim Rolph, Andrew Cheng, Kitty Yale The Liver Meeting 2023 (AASLD)

Oct 2023 | From Akero Therapeutics

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebocontrolled, phase 2b trial

Stephen A Harrison, Juan P Frias, Guy Neff, Gary A Abrams, K Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, for the HARMONY Study Group The Lancet Gastroenterology & Hepatology

Jun 2023 | From Akero Therapeutics

Noninvasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in patients with F2-F3 NASH: secondary analysis of Ph2b HARMONY study

Jörn M. Schattenberg, Juan Frias, Guy Neff, Gary A Abrams, Jeannie Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y. Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Erica Fong, Brittany de Temple, Doreen Chan, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, and Stephen A Harrison 2023 International Liver Congress (EASL)

Jun 2023 | From Akero Therapeutics

Characterization of the Patterns of Resolution of Histopathology After Efruxifermin Treatment of Patients with NASH Fibrosis (F2/3) for 24 Weeks

Cynthia Behling, Pierre Bedossa, Lan Shao, Erica Fong, Brittany de Temple, Doreen Chan, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, and Stephen A Harrison 2023 International Liver Congress (EASL)

Mar 2023 | From Akero Therapeutics

Efruxifermin, a long-acting, bivalent FGF21 analog, normalized noninvasive measures of liver injury, fibrosis, and metabolic health in patients with NASH and F2/F3 fibrosis over 24 weeks

Doreen Chan, Erik J Tillman, Reshma Shringarpure, Andrew Cheng, Stephen A Harrison, Kitty Yale, Tim Rolph Keystone Symposium: Metabolic and Molecular Mechanisms of NAFLD/NASH

Mar 2023 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrated improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

Erik J Tillman, Sina Bondza, Louben Dorval, Anna Boström, Tim Rolph Keystone Symposium: Metabolic and Molecular Mechanisms of NAFLD/NASH

Nov 2022 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrates improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

Erik J Tillman, Sina Bondza, Louben Dorval, Anna Boström, Tim Rolph The Liver Meeting 2022 (AASLD)

Aug 2022 | From Akero Therapeutics

Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health

Erik Tillman Keystone Symposium on Adipose Tissue and Metabolic Health

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline